Ocular Assessment of Patients Treated with Tamoxifen

Overview

Journal Cancer Treat Rep

Specialty Oncology

Date 1979 Nov 1

PMID 526917

Citations 7

Authors

M Beck

P V MILLS

Affiliations

Soon will be listed here.

Abstract

Tamoxifen is a specific estrogen antagonist used in the treatment of breast cancer. In a previous study, corneal and retinal changes were reported in four patients receiving high-dose tamoxifen therapy for greater than 1 year. Nineteen patients treated with tamoxifen for periods of 3 months to 4 years at normal dose levels have been studied and no ocular changes attributable to the drug were observed.

Citing Articles

Retinal function in patients treated with tamoxifen.

Watanabe S, Berezovsky A, Motono M, Sacai P, Pereira J, Sallum J Doc Ophthalmol. 2009; 120(2):137-43.

PMID: 19911210 DOI: 10.1007/s10633-009-9203-8.

A risk-benefit assessment of tamoxifen therapy.

Catherino W, Jordan V Drug Saf. 1993; 8(5):381-97.

PMID: 8504018 DOI: 10.2165/00002018-199308050-00005.

Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

Jordan V Br J Pharmacol. 1993; 110(2):507-17.

PMID: 8242225 PMC: 2175926. DOI: 10.1111/j.1476-5381.1993.tb13840.x.

Clinically important ocular reactions to systemic drug therapy.

Rennie I Drug Saf. 1993; 9(3):196-211.

PMID: 8240725 DOI: 10.2165/00002018-199309030-00005.

Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study.

Tormey D, Jordan V Breast Cancer Res Treat. 1984; 4(4):297-302.

PMID: 6394068 DOI: 10.1007/BF01806042.